Abed Arif, Critchlow Charlotte, Flatt Peter R, McClenaghan Neville H, Kelly Catriona
The Guy Hilton Research Centre, Institute for Science and Technology, Keele University UK.
Am J Stem Cells. 2012 Nov 30;1(3):196-204. Print 2012.
Exogenous insulin administration and oral anti-diabetic drugs are the primary means of treating diabetes. However, tight glycaemic control, with its inherent risk of hypoglycaemia, is required to prevent the microvascular and macrovascular complications of the disease. While islet or pancreas transplantations offer a longer-term cure, their widespread application is not possible, primarily because of a lack of donor tissue, the burden of life-long immunosuppression, and eventual graft rejection. The rapid increase in the incidence of diabetes has promoted the search for alternative cell-based therapies. Here we review recent advances in the directed differentiation of both endocrine and non-endocrine progenitors towards an islet-like phenotype.
外源性胰岛素给药和口服抗糖尿病药物是治疗糖尿病的主要手段。然而,为预防该疾病的微血管和大血管并发症,需要严格控制血糖,而这本身存在低血糖风险。虽然胰岛或胰腺移植可提供长期治愈方法,但由于缺乏供体组织、终身免疫抑制负担以及最终的移植物排斥反应,无法广泛应用。糖尿病发病率的迅速上升促使人们寻找基于细胞的替代疗法。在此,我们综述了内分泌和非内分泌祖细胞向胰岛样表型定向分化的最新进展。